Venture Capital

Features

Exscientia raises $100m Series C funding to develop fully autonomous drug design

Within nine months of closing a $60m Series C round, Oxford-headquartered artificial intelligence (AI) drug discovery company Exscientia has raised…

Features

Imcyse closes €21.3m Series B as new partner Pfizer takes equity stake

Features

TCR-T cell therapies for cancer: TScan raises $100m in Series C round

Features

Disease-cancelling drugs: Immuneering raises $62m in Series B round

Features

Spotlight on rare neurological diseases: Noema closes $60.8m Series A round

Features

Investing in innovative biotechs with Novo Ventures

Deals

SynOx raises €37m in Series A to develop emactuzumab for rare cancer TGCT

Features

Araris raises CHF15.2m to support its next-gen ADCs

Deals

Spotlight on rare NMOSD: Chord launches with $16m Series A round

Deals

Targeting PP2A to tackle cancers: Rappta closes €9m Series A round

Deals

Targeting the tumour stroma: Phenomic AI launches with $6m seed financing

Features

Tackling fibrosis: Galecto raises $64m in equity financing

Features

Next-gen gene editing: Graphite Bio launches with $45m funding

Features

Powering biologics development with spirulina: Lumen closes $16m Series B

Features

Advancing AAV gene therapy: Forge closes $40m Series A

Features

Linking cancer and fibrosis: iOnctura raises €20.1m in a Series A round

Features

Selva raises $3m to develop novel antiviral against Covid-19

Features

Transforming gliobastoma treatment: Imvax closes $112m Series C round

Features

Investing in late-stage companies: Forbion closes Growth Fund at €185m

Features

Exploring the promise of DUBs: Mission teams up with Pfizer

Features

Off-the-shelf NK cell therapies: Artiva closes $78m Series A round

Features

Autobahn Labs: virtual incubator launches with a focus on academia

Features

Eir Ventures launches to unlock the potential of the Nordics

Features

Ona’s €30m Series A round: directly targeting metastasis in cancer

Features

C4T raises $170m for human trials of degrader drugs

Features

Novo Ventures gives the nod to NodThera’s inflammatory disease innovations

Features

Spotlight on BaseLaunch: fostering innovative start-ups in Basel

Features

Promise of AI in drug discovery: Exscientia raises $60m in Series C round

Features

Covid-19 pandemic: overcoming big pharma’s infectious disease market failure

Features

Atea closes $215m Series D round to support Covid-19 trials

Features

Rapid Micro Biosystems raises $120m: improving contamination testing in pharma

Features

Three big pharma VC arms bet on FoRx’s novel cancer approach

Deals Analysis

Asia-Pacific witnesses 5.4% increase in deal activity during week ended 19 April 2020

Deals Analysis

Breakthrough in neurodegeneration: GV, Bill Gates and Foresight invest $45m in Cerevance

Deals Analysis

Global deal activity decreases 17.2% with 899 deals last week

Deals Analysis

Healthcare sector sees growth in deal activity for second consecutive week

Deals Analysis

Covid-19 impact: Global VC funding activity continues to remain subdued

Deals Analysis

Healthcare sector witnesses growth in deal activity despite Covid-19 concerns

Sign up to the newsletter: In Brief

I would also like to subscribe to:

Pharma Technology Focus : Pharmaceutical Technology Focus (monthly)

Thematic Take (monthly)

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close